Education
About Us
Working with TipRanks
Follow Us
Trubridge, Inc. (TBRG)
:TBRG
Top Page
TruBridge
(NASDAQ:TBRG)
52Neutral
TruBridge (TBRG) vs. S&P 500 (SPY)
Market Cap
$378.97M
Dividend YieldN/A
Average Volume (3M)172.11K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth1.05%
EPS Growth50.58%
CountryUS
Employees3,200
SectorHealthcare
Sector Strength69
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-1.56
Shares Outstanding14,949,387
10 Day Avg. Volume142,913
30 Day Avg. Volume172,112
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.20
Price to Cash Flow (P/CF)10.00
P/FCF Ratio16.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$28.67Price Target Upside13.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
TruBridge Business Overview & Revenue Model
Company DescriptionTruBridge, Inc. provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally. The company operates in three segments: Revenue Cycle Management (RCM), Electronic Health Record (HER), and Patient Engagement. It focuses on providing RCM solutions for care settings, regardless of primary healthcare information solutions provider along with business management, consulting, managed IT services, and analytics and business intelligence. The company provides acute care solutions and related services for community hospitals, and physician clinics; and patient engagement and empowerment technology solutions to improve patient outcomes and engagement strategies with care providers. In addition, it offers patient liability estimates eligibility verification, claim scrubbing and submission, remittance management, denial/audit management, and contract management; and offers RCM services, such as accounts receivable management, private pay service, medical coding, revenue cycle consulting, and other additional insurance and patient billing services. Further, it offers consulting and business management services; managed IT services; encoder solutions; patient management; financial accounting; clinical; patient care; and enterprise applications. Additionally, it offers TruBridge HER platform, including total system support, national client conference, continuing education, software releases, hardware replacement, cloud electronic health record, forms and supplies, and public cloud infrastructure services; post-acute care software systems, and support and maintenance services; and InstantPHR, an interactive portal and CHBase which funnels data from multiple sources into one platform. The company was formerly known as Computer Programs and Systems, Inc. and changed its name to TruBridge, Inc. in March 2024. TruBridge, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.
How the Company Makes MoneyTruBridge makes money through a diverse revenue model centered on providing essential services to healthcare organizations. Key revenue streams include subscription fees for its software solutions, service fees for revenue cycle management, and consulting fees for strategic advisory services. Additionally, TruBridge generates income from managed IT services, which help healthcare providers optimize their technology infrastructure. Significant partnerships with healthcare providers and technology partners enable TruBridge to expand its service offerings and maintain a steady flow of clients, contributing to its overall earnings.
TruBridge Financial Statement Overview
Summary
TruBridge faces challenges with profitability and growth, evidenced by negative net income and stagnant revenue. While the balance sheet is somewhat stable, with a reasonable debt-to-equity ratio, cash flow management needs improvement. The company should focus on strategic measures to enhance revenue and margin efficiency.Income Statement
The income statement of TruBridge shows a concerning trend with a significant net loss in the most recent year, driven by negative net income and EBIT margins. The gross profit margin has remained fairly stable, but revenue growth has stagnated. The company needs to focus on improving operational efficiency and returning to profitability.45
Neutral
Balance Sheet
TruBridge's balance sheet reflects a moderate level of stability with a reasonable debt-to-equity ratio. However, the decline in stockholders' equity and total assets over the years is a concern. The equity ratio indicates moderate leverage, but the company should address the decreasing equity trend to enhance financial strength.60
Neutral
Cash Flow
The cash flow statement indicates some resilience with positive free cash flow in the latest period. However, the operating cash flow to net income ratio suggests inefficiencies, as operating cash flow significantly surpasses net income. The company should focus on improving cash flow consistency and profitability alignment.55
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 342.65M | 339.44M | 326.65M | 280.63M | 264.49M | Gross Profit |
| 174.12M | 163.57M | 160.11M | 144.85M | 136.25M | EBIT |
| 6.63M | -42.60M | 22.78M | 24.71M | 21.05M | EBITDA |
| 34.94M | -15.39M | 47.73M | 43.11M | 35.56M | Net Income Common Stockholders |
| -23.08K | -45.79M | 15.87M | 18.43M | 14.25M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 12.32M | 3.85M | 6.95M | 11.43M | 12.67M | Total Assets |
| 394.43M | 434.42M | 430.96M | 383.35M | 326.27M | Total Debt |
| 5.27M | 203.29M | 147.24M | 106.46M | 83.43M | Net Debt |
| -7.05M | 199.44M | 140.29M | 95.03M | 70.76M | Total Liabilities |
| 225.74M | 247.80M | 199.25M | 160.78M | 126.27M | Stockholders Equity |
| 168.69M | 186.62M | 231.71M | 222.57M | 200.00M |
| Cash Flow | Free Cash Flow | |||
| 13.04M | -22.35M | 13.01M | 37.46M | 42.48M | Operating Cash Flow |
| 32.13M | 1.06M | 32.38M | 47.74M | 49.14M | Investing Cash Flow |
| 4.12M | -60.11M | -62.73M | -69.92M | -6.66M | Financing Cash Flow |
| -27.74M | 55.95M | 25.88M | 20.93M | -37.16M |
TruBridge Technical Analysis
Positive
25.35
Price Trends
27.18
Negative
24.21
Positive
18.41
Positive
Market Momentum
-0.62
Negative
47.61
Neutral
75.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TBRG, the sentiment is Positive. The current price of 25.35 is below the 20-day moving average (MA) of 25.38, below the 50-day MA of 27.18, and above the 200-day MA of 18.41, indicating a neutral trend. The MACD of -0.62 indicates Negative momentum. The RSI at 47.61 is Neutral, neither overbought nor oversold. The STOCH value of 75.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TBRG.
TruBridge Risk Analysis
TruBridge disclosed 44 risk factors in its most recent earnings report. TruBridge reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TruBridge Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $275.86M | 25.41 | 9.19% | ― | 22.54% | 8.55% | |
70 Outperform | $595.07M | 33.66 | 4.31% | ― | 51.09% | ― | |
67 Neutral | $345.05M | 20.99 | 8.27% | ― | 6.76% | -41.38% | |
52 Neutral | $378.97M | ― | -12.54% | ― | 1.05% | 50.58% | |
51 Neutral | $5.32B | 3.32 | -40.25% | 2.90% | 17.93% | 2.14% | |
46 Neutral | $306.48M | ― | -938.38% | ― | 38.82% | -645.78% | |
46 Neutral | $412.70M | ― | -63.28% | ― | 0.31% | -99.23% |
* Healthcare Sector Average
Performance Comparison
TBRG
TruBridge
25.35
17.02
204.32%
RNAC
Cartesian Therapeutics
11.83
-10.17
-46.23%
TCMD
Tactile Systems Technology
14.58
0.45
3.18%
VMD
Viemed Healthcare
7.07
-1.15
-13.99%
CSTL
Castle Biosciences
20.63
-0.90
-4.18%
DH
Definitive Healthcare Corp
2.71
-4.44
-62.10%
TruBridge Earnings Call Summary
Earnings Call Date: Mar 10, 2025 | % Change Since: -7.38% | Next Earnings Date: May 13, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant financial improvements, including revenue growth, improved cash flow, and successful integration of acquisitions. However, challenges in bookings and uncertainties related to healthcare funding present potential risks. Despite these challenges, the overall sentiment remains positive due to the strong financial performance and strategic initiatives in place.Highlights
Revenue Growth and Financial Improvement
Fourth quarter revenue reached $87.4 million, a 2% increase over the previous year. Adjusted EBITDA for the quarter was $17.2 million, a 44% increase year-over-year, with margins improving from 11.4% in Q1 to 20% by Q4. Cash flow from operations improved by $23 million compared to the previous year, reaching $10.3 million.
Full Year Financial Success
Revenue for fiscal year 2024 was $339 million, exceeding guidance. Adjusted EBITDA was $53.1 million, a 12% increase year-over-year. Cash flow from operations grew to $32 million from just over $1 million the previous year. The leverage ratio was reduced from 4 times to 3 times.
Successful Integration and Growth Initiatives
The integration of Viewgol, acquired in Q4 2023, is on track, with successful customer transitions underway. The nTrust offering showed growth with 24 deals in 2024, up from 18 in 2023 and 14 in 2022.
Operational Improvements and Leadership Enhancements
A new leadership team is in place to drive customer satisfaction and profitability. The global workforce strategy is progressing, with 30% of clients supported by a global team. Corporate governance enhancements included declassifying the Board and adding two independent directors.
Lowlights
Bookings Delays and Challenges
Q4 bookings were $14.3 million, below expectations due to delays in closing deals, some of which are expected to close in 2025. There is a potential for continued lumpiness in bookings due to changes in healthcare funding and larger deal concentrations.
Patient Care Revenue Decline
Patient Care revenue decreased by 6.3% in Q4 compared to the previous year, impacted by the sunsetting of Centriq and the divestiture of AHT.
Market Uncertainties
Uncertainty associated with changes in Washington regarding healthcare funding could impact deal timing. This has led to some delays and potential volatility in bookings.
Company Guidance
During the TruBridge Q4 2024 earnings call, the company provided guidance for 2025, highlighting several key metrics and strategic initiatives. For the full year 2025, TruBridge expects revenue between $345 million and $360 million, with adjusted EBITDA projected to range from $59 million to $66 million, indicating a focus on achieving mid-single-digit revenue growth and expanding EBITDA margins by approximately 200 basis points. In Q4 2024, TruBridge reported revenue of $87.4 million, a 2% increase from the previous year, and an adjusted EBITDA of $17.2 million, marking a 44% increase. The company also noted a significant improvement in cash flow from operations, which reached $10.3 million in Q4, a $23 million improvement compared to the previous year. For 2024, TruBridge achieved total revenue of $339 million and adjusted EBITDA of $53 million, surpassing their guidance ranges. The firm highlighted several strategic priorities for 2025, including enhancing customer satisfaction, increasing profitability, and driving growth through their nTrust offerings and expansion in hospitals with 100 to 400 beds.TruBridge Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
TruBridge Expands Board with New Cooperation Agreements
Positive
Feb 12, 2025
On February 11, 2025, TruBridge, Inc. announced cooperation agreements with Pinetree Capital Ltd. and Ocho Investments LLC, its two largest investors. Through these agreements, TruBridge expanded its board of directors by appointing Jerry Canada and Dris Upitis as independent directors, reflecting its commitment to strong corporate governance and value creation for stockholders. The agreements include initiatives like declassifying the board and terminating the stockholder rights plan, indicating a strategic move to enhance operational effectiveness and growth. The company’s CEO, Chris Fowler, emphasized that these changes align with TruBridge’s long-term strategy to capitalize on growth opportunities and strengthen its industry positioning.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.